Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice

Journal of Virology

Volumn 78, Issue 14, 2004, Pages 7418-7426

  Charlier, Nathalie ^a   Molenkamp, Richard ^b   Leyssen, Pieter ^a   Paeshuyse, Jan ^a   Drosten, Christian ^c   Panning, Marcus ^c   De Clercq, Erik ^a   Bredenbeek, Peter J ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CHIMERIC PROTEIN; ENVELOPE PROTEIN; PROTEIN E; PROTEIN PRM; UNCLASSIFIED DRUG; URIDINE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; DEATH; ENVELOPE GENE; FLAVIVIRUS; GENE SEQUENCE; IN VITRO STUDY; INOCULATION; MODOC FLAVIVIRUS; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; RNA ANALYSIS; RNA REPLICATION; RNA TRANSCRIPTION; SCID MOUSE; VERO CELL; VIRUS ENVELOPE; VIRUS GENE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PLAQUE; VIRUS STRAIN; VIRUS VIRULENCE; YELLOW FEVER FLAVIVIRUS;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; CRICETINAE; ENCEPHALITIS, VIRAL; FLAVIVIRUS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; RECOMBINATION, GENETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS; YELLOW FEVER VIRUS;

EID: 3142691278     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.14.7418-7426.2004     Document Type: Article

References (51)

1. Bray, M., R. Men, I. Tokimatsu, and C. J. Lai. 1998. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J. Virol. 72:1647-1651.
2. Bredenbeek, P. J., E. A. Kooi, B. Lindenbach, N. Huijkman, C. M. Rice, and W. J. Spaan. 2003. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J. Gen. Virol. 84:1261-1268.
3. Breitschopf, H., G. Suchanek, R. M. Gould, D. R. Colman, and H. Lassmann. 1992. In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol. 84:581-587.
4. Burke, D. S., and T. P. Monath. 2001. Flaviviruses, p. 1043-1125. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
5. Caufour, P. S., M. C. Motta, A. M. Yamamura, S. Vazquez, I. I. Ferreira, A. V. Jabor, M. C. Bonaldo, M. S. Freire, and R. Galler. 2001. Construction, characterization, and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res. 79:1-14.
6. Cecilia, D., and E. A. Gould. 1991. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization- resistant mutants. Virology 181:70-77.
7. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
8. Chambers, T. J., M. Halevy, A. Nestorowicz, C. M. Rice, and S. Lustig. 1998. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J. Gen. Virol. 79:2375-2380.
9. Chambers, T. J., A. Nestorowicz, P. W. Mason, and C. M. Rice. 1999. Yellow fever Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
10. Charlier, N., P. Leyssen, J. Paeshuyse, C. Drosten, H. Schmitz, A. Van Lommel, E. De Clercq, and J. Neyts. 2002. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J. Gen. Virol. 83:1887-1896.
11. Charlier, N., R. Molenkamp, P. Leyssen, A. M. Vandamme, E. De Clercq, P. Bredenbeek, and J. Neyts. 2003. A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses. J. Virol. Methods 108:67-74.
12. Drosten, C., S. Gottig, S. Schilling, M. Asper, M. Panning, H. Schmitz, and S. Gunther. 2002. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J. Clin. Microbiol. 40:2323-2330.
13. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
14. Guirakhoo, F., K. Pagachev, J. Arroyo, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
15. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:5477-5485.
16. Guirakhoo, F., Z. X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
17. Halevy, M., Y. Akov, N. D. Ben, D. Kobiler, B. Lachmi, and S. Lustig. 1994. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch. Virol. 137:355-370.
18. Hasegawa, H., M. Yoshida, T. Shiosaka, S. Fujita, and Y. Kobayashi. 1992. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology 191:158-165.
19. Holzmann, H., F. X. Heinz, C. W. Mandl, F. Guirakhoo, and C. Kunz. 1990. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 64:5156-5159.
20. Jiang, W. R., A. Lowe, S. Higgs, H. Reid, and E. A. Gould. 1993. Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J. Gen. Virol. 74(Pt. 5):931-935.
21. Johnson, H. N. 1967. Ecological implications of antigenically related mammalian viruses for which arthropod vectors are unknown and avian associated soft tick viruses. Jpn. J. Med. Sci. Biol. 20:160-166.
22. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631-664.
23. Leyssen, P., N. Charlier, P. Lemey, F. Billoir, A.-M. Vandamme, E. De Clercq, X. de Lamballerie, and J. Neyts. 2002. Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology 239:125-140.
24. Leyssen, P., R. Croes, P. Rau, S. Heiland, E. Verbeken, R. Sciot, J. Paeshuyse, N. Charlier, E. De Clereq, U. Meyding-Lamade, and J. Neyts. 2003. Acute encephalitis, a poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus infections. Brain Pathol. 13:279-290.
25. Leyssen, P., J. Paeshuyse, N. Charlier, A. Van Lommel, C. Drosten, E. De Clercq, and J. Neyts. 2003. Impact of direct virus-induced neuronal dysfunction and immunological damage on the progression of flavivirus (Modoc) encephalitis in a murine model. J. Neurovirol. 9:69-78.
26. Leyssen, P., A. Van Lommel, C. Drosten, H. Schmitz, E. De Clercq, and J. Neyts. 2001. A novel model for the study of the therapy of Flavivirus infections using the Modoc virus. Virology 279:27-37.
27. Lindenbach, B. D., and C. M. Rice. 1997. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 71:9608-9617.
28. Mandl, C. W., S. L. Allison, H. Holzmann, T. Meixner, and F. X. Heinz. 2000. Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J. Virol. 74:9601-9609.
29. McMinn, P. C. 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. J. Gen. Virol. 78:2711-2722.
30. McMinn, P. C., L. Dalgarno, and R. C. Weir. 1996. A comparison of the spread of Murray Valley encephalitis viruses of high or low neuroinvasiveness in the tissues of Swiss mice after peripheral inoculation. Virology 220:414-423.
31. McMinn, P. C., E. Lee, S. Hartley, J. T. Roehrig, L. Dalgarno, and R. C. Weir. 1995. Murray valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice. Virology 211:10-20.
32. McMinn, P. C., I. D. Marshall, and L. Dalgarno. 1995. Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line. J. Gen. Virol. 76:865-872.
33. Molenkamp, R., E. A. Kooi, M. A. Lucassen, S. Greve, J. C. Thijssen, W. J. Spaan, and P. J. Bredenbeek. 2003. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J. Virol. 77:1644-1648.
34. Monath, T. P. 2001. Prospects for development of a vaccine against the West Nile virus. Ann. N. Y. Acad. Sci. 951:1-12.
35. Monath, T. P., J. Arroyo, C. Miller, and F. Guirakhoo. 2001. West Nile virus vaccine. Curr. Drug Targets Infect. Disord. 1:37-50.
36. Monath, T. P., and F. X. Heinz. 1996. Flaviviruses, p. 961-1034. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
37. Monath, T. P., K. Soike, L. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. T. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax[trade]) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine 17:1869-1882.
38. Ni, H., and A. D. Barrett. 1996. Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness. J. Gen. Virol. 77(Pt. 7):1449-1455.
39. Nickells, M., and T. J. Chambers. 2003. Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J. Virol. 77:12232-12242.
40. Pletnev, A. G. 2001. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3′ deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice. Virology 282:288-300.
41. Pletnev, A. G., M. Bray, and C. J. Lai. 1993. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 67:4956-4963.
42. Pletnev, A. G., G. G. Karganova, T. I. Dzhivanyan, V. A. Lashkevich, and M. Bray. 2000. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. Virology 274:26-31.
43. Pletnev, A. G., R. Putnak, J. Speicher, E. J. Wagar, and D. W. Vaughn. 2002. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA 99:3036-3041.
44. Rice, C. M., A. Grakoui, R. Galler, and T. J. Chambers. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
45. Ryman, K. D., T. N. Ledger, G. A. Campbell, S. J. Watowich, and A. D. Barrett. 1998. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 244:59-65.
46. Ryman, K. D., H. Xie, T. N. Ledger, G. A. Campbell, and A. D. Barrett. 1997. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230:376-380.
47. Schlesinger, J. J., M. W. Brandriss, and T. P. Monath. 1983. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology 125:8-17.
48. Sumiyoshi, H., G. H. Tignor, and R. E. Shope. 1995. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171:1144-1151.
49. van der Most, R. G., K. Murali-Krishna, R. Ahmed, and J. H. Strauss. 2000. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74:8094-8101.
50. van Dinten, L. C., J. A. den Boon, A. L. Wassenaar, W. J. Spaan, and E. J. Snijder. 1997. An infectious arterivirus cDNA clone: identification of a replicase point mutation that abolishes discontinuous mRNA transcription. Proc. Natl. Acad. Sci. USA 94:991-996.
51. Wittwer, C. T., K. M. Ririe, R. V. Andrew, D. A. David, R. A. Gundry, and U. J. Balis. 1997. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. BioTechniques 22:176-181.